<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05089188</url>
  </required_header>
  <id_info>
    <org_study_id>8420</org_study_id>
    <nct_id>NCT05089188</nct_id>
  </id_info>
  <brief_title>PRAME Immunohistochemistry as an Adjunct for Evaluating Ambiguous Melanocytic Proliferation</brief_title>
  <acronym>ANTIPRAME</acronym>
  <official_title>PRAME Immunohistochemistry as an Adjunct for Evaluating Ambiguous Melanocytic Proliferation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Skin melanoma is a common form of skin cancer. Its diagnosis is usually clinically suspected&#xD;
      and then affirmed by histopathological examination.&#xD;
&#xD;
      In some cases, the histopathological analysis of these lesions is equivocal, and the&#xD;
      malignant or benign nature of the proliferation is difficult to determine with certainty. In&#xD;
      these cases, the use of expensive ancillary tests, which are hardly accessible and take a&#xD;
      long time to set up (FISH - CGH-array), is usually required.&#xD;
&#xD;
      Anti-PRAME immunostaining, an inexpensive and readily available technic, has recently been&#xD;
      described as highly sensitive and specific for diagnosing malignant melanocytic&#xD;
      proliferations. Knowledge on its utility for evaluating ambiguous melanocytic neoplasms&#xD;
      remains limited.&#xD;
&#xD;
      Our study aims to improve the current body of knowledge on the utility of PRAME&#xD;
      immunohistochemistry for evaluating challenging samples of melanocytic proliferation. The&#xD;
      secondary objective is to determine the PRAME immunoreactivity profile for each histological&#xD;
      subtype of melanocytic proliferations (spitzoid tumors, cellular blue nevi, dysplastic nevi&#xD;
      ...)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immunomarkers</measure>
    <time_frame>1 month</time_frame>
    <description>Correlation of melanocytic lesions' histopathological diagnosis concerning benignity or malignancy with anti-PRAME immunohistochemical expression profile</description>
  </primary_outcome>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Melanoma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Immunomarkers</intervention_name>
    <description>immunohistochemical expression profile of ambiguous melanocytic proliferation.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All cases with histopathological diagnosis of &quot;ambiguous melanocytic proliferation&quot; or&#xD;
        &quot;atypical melanocytic proliferation&quot; made between January 2016 and December 2020.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient at the time of diagnosis (&gt; = 18 years).&#xD;
&#xD;
          -  histopathological diagnosis of &quot;ambiguous melanocytic proliferation&quot; or &quot;atypical&#xD;
             melanocytic proliferation&quot; made between January 2016 and December 2020.&#xD;
&#xD;
          -  Histological slides archived in the &quot;CRB&quot; biobank available&#xD;
&#xD;
          -  Formalin-fixed paraffin-embedded tissue block archived in the &quot;CRB&quot; biobank available&#xD;
&#xD;
          -  Informed patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who has expressed opposition to participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Les HÃ´pitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mona MITCOV</last_name>
      <phone>+33 3 88 11 73 77</phone>
      <email>Mona.MITCOV@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Mona MITCOV</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonin FATTORI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 11, 2021</study_first_submitted>
  <study_first_submitted_qc>October 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunohistochemistry</keyword>
  <keyword>Histopathology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

